Russell Investments Group Ltd. increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 20.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 944,240 shares of the biopharmaceutical company’s stock after acquiring an additional 160,141 shares during the quarter. Russell Investments Group Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $14,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $355,746,000. Bank of America Corp DE purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $38,347,000. Jefferies Financial Group Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $31,040,000. Eagle Health Investments LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $29,521,000. Finally, Palo Alto Investors LP acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at about $19,916,968. 97.67% of the stock is currently owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Stock Performance
RARE stock opened at $17.22 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $12.73 and a one year high of $39.89. The firm’s fifty day moving average is $15.46 and its 200 day moving average is $22.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. During the same period in the prior year, the business posted ($1.81) EPS. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.21 earnings per share for the current fiscal year.
Insider Buying and Selling at Ultragenyx Pharmaceutical
In related news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the transaction, the chief financial officer owned 89,229 shares in the company, valued at $1,362,526.83. The trade was a 7.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 8,510 shares of company stock valued at $127,561. 5.20% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
RARE has been the topic of a number of recent research reports. Guggenheim lowered their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Citigroup reduced their price target on Ultragenyx Pharmaceutical from $32.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, November 5th. Wells Fargo & Company boosted their price target on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Wednesday, November 4th. TD Cowen upped their price objective on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Finally, Robert W. Baird lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $40.00 to $16.00 in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $29.79.
Read Our Latest Research Report on Ultragenyx Pharmaceutical
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
Featured Articles
- Five stocks we like better than Ultragenyx Pharmaceutical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
